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BRIEF REPoRT
Abstract: The combination of sunitinb (37.5 mg orally daily) + pacli-
taxel (90 mg/m2 intravenously on days 1, 8, 15 every 4 weeks) was 
examined in patients with advanced esophageal or gastroesophageal 
junction cancer, and progression-free survival (PFS) was compared 
to that of historical controls. The end points included response rate, 
overall survival, and toxicities. Twenty-eight patients were enrolled 
at six centers. Median age was 59.5 years. The 24-week PFS rate was 
25% (90% confidence interval [CI], 12–42%). Three (11%) of 23 
evaluable patients had a response (1 complete response and 2 partial 
response) (90% CI, 3−25%). Median overall survival was 228 days 
(90% CI, 140–283 days). Grade 3/4 toxicities included leukopenia/
neutropenia (25%), anemia (18%), fatigue (11%), and hemorrhage 
(11%). There were four grade 5 toxicities including upper gastroin-
testinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 
1), and unexplained death (n = 1). In our study, we found that suni-
tinib + paclitaxel in patients with advanced esophageal or gastroe-
sophageal junction cancer had a 24-week PFS no better than the PFS 
of historical controls. The combination also had a high rate of serious 
toxicities and will not be pursued.
Key Words: Sunitinib, Paclitaxel, Esophageal, Gastroesophageal 
junction, Angiogenesis, Tyrosine kinase inhibitors.
(J Thorac Oncol. 2012;7: 760–763)
Despite advances in staging and treatment for patients with esophageal cancer, the relative 5-year survival rate for all 
stages remained at an estimated 19% between 1999 and 2005.1 
Response rates (RRs) to classic chemotherapeutic regimens 
range from 15 to 48% and are typically short in duration.2,3 
Angiogenesis is a critical factor in tumor growth and meta-
static spread. In patients with esophageal cancer, 30 to 60% of 
them have overexpression of vascular endothelial growth fac-
tor (VEGF), which has been correlated with greater microves-
sel density, advanced disease, and poor prognosis.4 Inhibition 
of angiogenesis with compounds like sunitinib maleate, a 
well-tolerated oral inhibitor of tyrosine kinase with activity 
against VEGF receptors (types 1–3), platelet-derived growth 
factor a and platelet-derived growth factor , c-kit, and 
fetal liver tyrosine kinase receptor 3,5 is a novel therapeutic 
approach that has demonstrated activity in a variety of malig-
nancies. In preclinical studies, gastric and esophageal cancer 
cell lines overexpressed VEGF, proliferated in the presence of 
recombinant VEGF, and were inhibited in a dose-dependent 
manner by sunitinib.6 Sunitinib has been studied for locally 
advanced esophageal cancer7 and studies in patients with 
relapsed/refractory metastatic disease are ongoing. on the 
basis of this preclinical and clinical work, the known overex-
pression of VEGF in esophageal cancer, the hypothesized syn-
ergy between VEGF inhibition, and the antiangiogenic effects 
of taxane therapy,4 we conducted this multi-institutional phase 
II study to evaluate the efficacy of sunitinib + paclitaxel in 
patients with advanced esophageal or gastroesophageal (GE) 
junction carcinoma.
PATIENTS AND METHODS
Patients enrolled on study included adults with histo-
logically proven recurrent or metastatic esophageal or GE 
junction squamous cell or adenocarcinoma, who had received 
less than two chemotherapy regimens for locally advanced or 
metastatic disease, and had measurable and/or evaluable dis-
ease as per the Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria. All patients had an Eastern Cooperative 
oncology Group performance status of 0 to 2. Key exclusion 
criteria included prior exposure to an epidermal growth factor 
receptor inhibitor or any other antiangiogenic agents.
Each treatment cycle was defined as 28 days and included 
paclitaxel 90 mg/m2 intravenous infusion over 60 minutes on 
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days 1, 8, and 15 and sunitinib maleate 37.5 mg orally daily.8 
Participants were scheduled to receive four cycles of the com-
bination therapy. Treatment was discontinued upon disease 
progression or unacceptable toxicity. After four cycles, pacli-
taxel was discontinued and each patient was allowed to con-
tinue on sunitinib maleate for two more cycles provided he/
she did not have disease progression, intolerable side effects, 
or adverse reactions.
Patients were evaluated at the beginning of each treat-
ment cycle. Before odd-numbered cycles, a disease evalu-
ation per RECIST criteria was performed. At the end of 
the study, patients, including those who discontinued pro-
tocol therapy early, were evaluated 30 days after the last 
dose. Patients were then serially followed up for duration 
of response and for survival. All toxicities were measured 
according to the National Cancer Institute Common Toxicity 
Criteria version 3.0.
The primary end point was the rate of nonprogressive 
disease at 6 months. Nonprogressive disease was defined as a 
complete response, partial response, or stable disease. A pre-
determined improvement from 25 to 50% in nonprogressive 
disease rate was deemed reasonable for the proposed regimen 
as two prior phase II trials of paclitaxel therapy alone dem-
onstrated a median duration of response ranging from 119 to 
172 days9,10 and we anticipated prolonged duration of response 
with the addition of antiangiogenic therapy. With 26 subjects, 
the study had more than 80% power based on one-sided test 
with error rate controlled at 5%.
RESULTS
Twenty-eight patients were enrolled at six participating 
centers. Patient demographics and disease characteristics are 
summarized in Table 1. over 80% of the participants were 
men, with a median age at enrollment of 59.5 years (age range 
of 40–84 years). All tumors were located in the esophagus 
(22/28 or GE junction [6/28]). Ninety-three percent of the 
tumors (n = 26) were adenocarcinoma and 7% (n = 2) were 
squamous cell carcinoma. Nine of 28 patients had received 
prior chemotherapy.
The median follow-up was 222 days, with a range 
of 15 to 629 days. Six patients (22%) completed less than 
one cycle of therapy. Seven patients (25%) finished all 
four cycles and went on to receive maintenance treatment 
(median length of maintenance treatment was 54 days). 
At the end of the study, 23 patients (82%) were evaluable. 
Five patients were not evaluable owing to no postbase-
line assessment. Reasons for coming off study included 
death caused by progressive disease (n = 20 [71%]), death 
caused by other reasons (n = 2 [7%]), and refusal to fol-
low-up (n = 1 [4%]). Among the 28 patients, 10 (36%) 
had dose modification and 16 (57%) had dose delay of 
sunitinib. Fifteen (54%) had dose modification of paclitaxel, 
and 14 (50%) had dose delay of paclitaxel.
Toxicity data for all patients are summarized in Tables 
2 through 4. The most common toxicities reported included 
fatigue, anemia, and leukopenia/neutropenia. Grade 3 and 
grade 4 toxicities included leukopenia/neutropenia (25%), 
anemia (18%), fatigue (11%), and hemorrhage (11%). There 
were four grade 5 toxicities including two deaths caused by 
upper gastrointestinal hemorrhage and one caused by gastro-
intestinal/esophageal fistula (Table 4). Three of the four events 
were considered treatment-related deaths. Sunitinib-related 
toxicities including diarrhea, rash, hemorrhage, thrombosis, 
and hypertension were also observed.
The 24-week progression-free survival (PFS) rate was 
25% (7/28) (90% CI, 12–42%) for the combined regimen. of 
the 23 evaluable patients, 3 (11%) had a measurable response 
by RECIST criteria (90% CI, 3−25%). A complete response 
was observed in one patient and partial response observed in 
two patients. For the three patients who responded, the dura-
tions of response were 29, 56, and 72 days, respectively. For 
the 28 intention-to-treat patients, the 1-year overall survival 
(oS) rate was 20% (90% CI, 9−34%). Median oS was 228 
days (90% CI, 140–283 days). The median PFS was 112 days 
(90% CI, 54–150).
TABLE 1. Demographics (Intention to Treat n = 28)
Characteristics
Category/
Statistics n/Value %
Sex Female 5 18
Male 23 82
Race Caucasian 27 96
African American 1 4
Ethnicity Non-Hispanic 27 96
Not reported 1 4
Age Median 59.5 yr
Range 40–84 yr
ECoG PS 0 15 54
1 11 39
2 2 7
Tumor site Esophagus 22 79
Gastroesophageal 
junction
6 21
Histology Adenocarcinoma 26 93
Squamous cell 
carcinoma
2 7
Prior treatment Yes 11 (9 with prior 
chemo)
39
No 17 61
ECoG PS, Eastern Cooperative oncology Group performance status.
TABLE 2. Selected Hematologic Toxicities Irrespective of 
Causality Attributed (n = 28)
Grade 3 Grade 4 Grade 3/4
Leukopenia/neutropenia 6 21% 1 4% 7 25%
Anemia 3 11% 2 7% 5 18%
Thrombocytopenia 1 4% 0 — 1 4%
Febrile neutropenia (fever 
without clinically or 
microbiologically 
documented infection) 
(ANC <1.0, fever 
≥38.5°C)
1 4% 0 — 1 4%
ANC, absolute neutrophil count.
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DISCUSSION
The results of this multi-institutional phase II trial 
are, to our knowledge, the first reported study of sunitinib in 
advanced esophageal/GE junction cancer. This combination 
did not meet our predetermined goal of improved nonprogres-
sive disease from 25 to 50% at 24 weeks. The majority of the 
patients completed less than two cycles and toxicities were 
significant with at least three treatment-related deaths.
Paclitaxel alone as first-line therapy for metastatic disease 
has demonstrated an RR ranging from 15 to 32% in two prior 
phase II studies of patients with advanced esophageal cancer.9,10 
This is inferior to RRs reported with use of regimens such as 
epirubicin + cisplatin + fluorouracil and epirubicin + oxaliplatin 
+ capecitabine or paclitaxel containing combination regimens 
that have yielded higher RRs (40–54%) at the expense of higher 
toxicity rates, including docetaxel + cisplatin + 5-fluorouracil,11 
and oxaliplatin + paclitaxel.12 our study failed to show similar 
RRs with a reported overall RR of only 11% and a 24-week PFS 
rate estimated at 25% with increased toxicities.
VEGF inhibitors have been studied in patients with 
advanced esophageal cancer. In a phase II study combining irino-
tecan, cisplatin and bevacizumab,13 a 65% overall RR was noted 
with a median time to progression of 8.3 months and a median 
survival of 12.3 months. A second study looking at docetaxel + 
cisplatin + 5-FU + bevacizumab demonstrated an improvement 
in PFS at 6 months from a historic control of 43% for docetaxel 
+ cisplatin + fluorouracil alone to 79% with the addition of beva-
cizumab.14 Grade 3 or 4 toxicities in both of these studies were 
fewer than appreciated in our study. Another study evaluating 
bevacizumab + cisplatin and capecitabine in advanced gastric 
cancer reported fewer serious toxicities than observed in our 
study, and although this study showed significant improvements 
in the overall RR and PFS, it failed to meet its primary end point 
of improved oS (10.1 versus 12.1 months [p = 0.1]).15
Sunitinib has been evaluated in esophageal cancer in the 
adjuvant setting, looking at neoadjuvant irinotecan + cisplatin 
combined with radiation followed by esophagectomy followed 
by adjuvant sunitinib therapy. In this phase II study, 70 patients 
were enrolled; following esophagectomy only 20 patients were 
fit enough to receive sunitinib therapy. Median oS in this 
locally advanced population was 26 months with a 2-year oS 
of around 50%. Specific toxicity data are not yet available.7 
Currently, there is an ongoing phase II study comparing suni-
tinib single agent to placebo therapy in relapsed or refractory 
esophageal or GE junction carcinoma (ClincalTrials.gov ID 
#NCT00702884). The sunitinib-specific toxicities observed in 
our study were similar to those previously reported; however, 
the increased incidence of grade 3/4/5 hemorrhage was con-
cerning with this combination and was not previously reported 
in therapy with taxanes alone, combination regimens contain-
ing taxanes, or with other VEGF inhibitors. In conclusion, our 
study of the combination of sunitinib + paclitaxel in advanced 
esophageal and GE junction cancer was negative as it did not 
meet our primary end point of 50% PFS at 24 weeks, and with 
a high rate of serious toxicities, including four grade-5 events, 
this combination will not be pursued further.
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